Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Online First
Meeting Highlights
ESMO 2021 Highlights
Study Shows mRNA COVID-19 Vaccine Effective and Safe in Patients with Cancer Undergoing Treatment
Read More
Online First
Meeting Highlights
ESMO 2021 Highlights
Trastuzumab Deruxtecan Tops Trastuzumab Emtansine as Second-Line Therapy in HER2-Positive Metastatic Breast Cancer
Read More
Online First
Meeting Highlights
ESMO 2021 Highlights
Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer
Read More
Online First
Meeting Highlights
ESMO 2021 Highlights
Adagrasib Shows Promising Activity in Metastatic Colorectal Cancer
Read More
RESOLVE: Significant Improvement in 3-Year Disease-Free Survival with Use of Perioperative SOX in Patients with Locally Advanced Gastric Cancer
Read More
Zanidatamab plus Standard First-Line Chemotherapy Demonstrates Promising Antitumor Activity in Patients with HER2-Positive GEA
Read More
DESTINY-Gastric02: Clinical Efficacy Found with Use of Second-Line Trastuzumab Deruxtecan in Patients with Metastatic Gastric or Esophageal Junction Cancer
Read More
Analysis of the Prognostic Value of Immune Checkpoints in Gastric Adenocarcinoma
Read More
PANTHERA: Triplet Pembrolizumab, Trastuzumab, and Chemotherapy First-Line Therapy Is Effective in HER2-Positive Advanced Gastric/GEJ Cancer Regardless of PD-L1 Status
Read More
ATTRACTION-2: Nivolumab Conveys Survival Benefit for Patients with Advanced Gastric/GEJ Cancer When Used as Treatment Beyond Progression
Read More
78
79
80
81
82
83
84
Page 81 of 200
Results 801 - 810 of 1993
